nach oben

Current Hepatology Reports

Erschienen in:

22.06.2020 | Hepatitis B (JK Lim, Section Editor)

Point of Care Diagnostic Testing for Hepatitis B Virus

verfasst von: Kathy Jackson, Robert G. Gish

Erschienen in: Current Hepatology Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

As we strive to reach the World Health Organization (WHO) goal of eliminating viral hepatitis as a public health threat by 2030, point of care tests (POCTs) will be important in low- to middle-income and developed countries. This review aims to investigate available POCT choices for hepatitis B virus (HBV) and to provide an algorithm for screening, assessing, and monitoring chronic HBV.

Recent Findings

There are 3 WHO pre-qualified rapid diagnostic assays for hepatitis B surface antigen (HBsAg) that are sensitive, specific, and reliable in screening for HBV: SD Bioline, Determine 2, and VIKIA. POCTs for other biomarkers are less reliable and sensitive but have some applicability. The Xpert® HBV Viral Load assay is sensitive and specific with a wide dynamic range.

Summary

While POCT for HBeAg and HBV antibodies require improvement, HBsAg POCT and the Xpert® HBV Viral Load assay are reliable and available now.

Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Infect Dis. 2017;17(Suppl 1):699. https://doi.org/10.1186/s12879-017-2775-0.CrossRefPubMedPubMedCentral

Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO member state responses 2017. JHEP. 2019;1(2):81–9. https://doi.org/10.1016/j.jhepr.2019.04.002.

Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. https://doi.org/10.1016/S2468-1253(18)30056-6.CrossRef

World Health Organization. Global health sector strategy on viral hepatitis. 2016-2021. Published in June 2016. www.who.int/hepatitis/strategy2016-2021/ghss-hep/en. Accessed 24 April 2020.

Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167–228. https://doi.org/10.1016/S2468-1253(19)30342-5.CrossRefPubMed

Kramvis A. Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa. Curr Opin HIV AIDS. 2020;15:185–92. https://doi.org/10.1097/COH.0000000000000619.CrossRefPubMed

Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502–7. https://doi.org/10.1016/j.jhep.2014.04.038.CrossRefPubMed

Bittaye M, Idoko P, Ekele BA, Obed SA, Nyan O. Hepatitis B virus sero-prevalence amongst pregnant women in the Gambia. BMC Infect Dis. 2019;19(1):259. https://doi.org/10.1186/s12879-019-3883-9.CrossRefPubMedPubMedCentral

Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. Curr Opin HIV AIDS. 2017;12(3):302–14. https://doi.org/10.1097/COH.0000000000000370.CrossRefPubMedPubMedCentral

10.

Duchesne L, Lacombe K. Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J Viral Hepat. 2018;25(2):108–17. https://doi.org/10.1111/jvh.12827.CrossRefPubMed

11.

Peeling RW, McNerney R. Emerging technologies in point-of-care molecular diagnostics for resource-limited settings. Expert Rev Mol Diagn. 2014;14(5):525–34. https://doi.org/10.1586/14737159.2014.915748.CrossRefPubMed

12.

Jackson K, Locarnini S, Gish R. Diagnostics of hepatitis B virus: standard of care and investigational. Clin Liver Dis (Hoboken). 2018;12(1):5–11. https://doi.org/10.1002/cld.729.CrossRefPubMedCentral

13.

Chai N, Chang HE, Nicolas E, Han Z, Jarnik M, Taylor J. Properties of subviral particles of hepatitis B virus. J Virol. 2008;82(16):7812–7. https://doi.org/10.1128/JVI.00561-08.CrossRefPubMedPubMedCentral

14.

Jiang B, Himmelsbach K, Ren H, Boller K, Hildt E. Subviral hepatitis B virus filaments, like infectious viral particles, are released via multivesicular bodies. J Virol. 2015;90(7):3330–41. https://doi.org/10.1128/JVI.03109-15.CrossRefPubMed

15.

Hong T, Yang H, Kao J. Role of HBsAg testing in the management of patients. Curr Hepatol Rep. 2019;18:331–41. https://doi.org/10.1007/s11901-019-00484-y.CrossRef

16.

Allain JP, Opare-Sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol. 2016;13(11):643–53. https://doi.org/10.1038/nrgastro.2016.138.CrossRefPubMed

17.

Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, et al. A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. J Viral Hepat. 2014;21(12):905–8. https://doi.org/10.1111/jvh.12257.CrossRefPubMedPubMedCentral

18.

Khuroo MS, Khuroo NS, Khuroo MS. Accuracy of rapid point-of-care diagnostic tests for hepatitis B surface antigen-a systematic review and meta-analysis. J Clin Exp Hepatol. 2014;4(3):226–40. https://doi.org/10.1016/j.jceh.2014.07.008.CrossRefPubMedPubMedCentral

19.

Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhardt H, Grunert HP, et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang. 2010;98(3 Pt 2):403–14. https://doi.org/10.1111/j.1423-0410.2009.01272.x.CrossRefPubMedPubMedCentral

20.

Alavian SM, Carman WF, Jazayeri SM. HBsAg variants: diagnostic-escape and diagnostic dilemma. J Clin Virol. 2013;57(3):201–8. https://doi.org/10.1016/j.jcv.2012.04.027.CrossRefPubMed

21.

Hirzel C, Pfister S, Gorgievski-Hrisoho M, Wandeler G, Zuercher S. Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples. J Clin Virol. 2015;69:33–5. https://doi.org/10.1016/j.jcv.2015.05.024.CrossRefPubMed

22.

Servant-Delmas A, Ly TD, Hamon C, Houdah AK, Laperche S. Comparative performance of three rapid HBsAg assays for detection of HBs diagnostic escape mutants in clinical samples. J Clin Microbiol. 2015;53(12):3954–5. https://doi.org/10.1128/JCM.02117-15.CrossRefPubMedPubMedCentral

23.

Amini A, Varsaneux O, Kelly H, Tang W, Chen W, Boeras DI, et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):698. https://doi.org/10.1186/s12879-017-2772-3.CrossRefPubMedPubMedCentral

24.

Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J Clin Microbiol. 2015;53(4):1156–63. https://doi.org/10.1128/JCM.02980-14.CrossRefPubMedPubMedCentral

25.

• Murayama A, Momose H, Yamada N, Hoshi Y, Muramatsu M, Wakita T, et al. Evaluation of in vitro screening and diagnostic kits for hepatitis B virus infection. J Clin Virol. 2019;117:37–42. https://doi.org/10.1016/j.jcv.2019.05.011Murayama et al – This manuscript compares the Determine HBsAg and the Determine 2 HBsAg sensitivities, which have not been published elsewhere to our knowledge.

26.

Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, et al. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol. 2013;58(3):473–8. https://doi.org/10.1016/j.jhep.2012.11.016.CrossRefPubMed

27.

Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018;69(4):916–26. https://doi.org/10.1016/j.jhep.2018.05.017.CrossRefPubMed

28.

Chisenga CC, Musukuma K, Chilengi R, Zurcher S, Munamunungu V, Siyunda A, et al. Field performance of the Determine HBsAg point-of-care test for diagnosis of hepatitis B virus co-infection among HIV patients in Zambia. J Clin Virol. 2018;98:5–7. https://doi.org/10.1016/j.jcv.2017.11.005.CrossRefPubMed

29.

Kweon OJ, Lim YK, Kim HR, Kim TH, Lee MK. Analytical performance of newly developed rapid point-of-care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples. J Med Virol. 2019;91(6):1056–62. https://doi.org/10.1002/jmv.25405.CrossRefPubMed

30.

•• World Health Organization. WHO list of prequalified in vitro diagnostics. www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/. Accessed 24 April 2020. WHO – WHO pre-qualification website is an excellent reference for researching pre-qualified in vitro diagnostics such as rapid diagnostic tests.

31.

Farooq A, Waheed U, Zaheer HA, Aldakheel F, Alduraywish S, Arshad M. Detection of HBsAg mutants in the blood donor population of Pakistan. PLoS One. 2017;12(11):e0188066. https://doi.org/10.1371/journal.pone.0188066.CrossRefPubMedPubMedCentral

32.

Upreti SR, Gurung S, Patel M, Dixit SM, Krause LK, Shakya G, et al. Prevalence of chronic hepatitis B virus infection before and after implementation of a hepatitis B vaccination program among children in Nepal. Vaccine. 2014;32(34):4304–9. https://doi.org/10.1016/j.vaccine.2014.06.027.CrossRefPubMedPubMedCentral

33.

Segeral O, N'Diaye DS, Prak S, Nouhin J, Chhun S, Khamduang W, et al. Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study. J Clin Virol. 2018;109:29–34. https://doi.org/10.1016/j.jcv.2018.10.007.CrossRefPubMed

34.

Poiteau L, Soulier A, Roudot-Thoraval F, Hezode C, Challine D, Pawlotsky JM, et al. Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations. J Clin Virol. 2017;96:64–6. https://doi.org/10.1016/j.jcv.2017.09.012.CrossRefPubMed

35.

Cruz HM, de Paula SL, Salete de Paula V, Miguel JC, do ÓO KM R, Pádua Milagres FA, et al. Poor sensitivity of rapid tests for the detection of antibodies to the hepatitis B virus: implications for field studies. Mem Inst Oswaldo Cruz. 2017;112(3):209–13. https://doi.org/10.1590/0074-02760160394.CrossRefPubMedPubMedCentral

36.

El-Ghitany EM, Farghaly AG. Evaluation of commercialized rapid diagnostic testing for some hepatitis B biomarkers in an area of intermediate endemicity. J Virol Methods. 2013;194(1–2):190–3. https://doi.org/10.1016/j.jviromet.2013.08.026.CrossRefPubMed

37.

Wu FY, Liao YW, Wu JF, Chen HL, Hsu HY, Chang MH, et al. A simple and rapid test-card method to detect hepatitis B surface antigen and antibody: potential application in young children and infants. Pediatr Neonatol. 2016;57(3):219–24. https://doi.org/10.1016/j.pedneo.2015.07.003.CrossRefPubMed

38.

Seck A, Ndiaye F, Maylin S, Ndiaye B, Simon F, Funk AL, et al. Poor sensitivity of commercial rapid diagnostic tests for hepatitis B e antigen in Senegal, West Africa. Am J Trop Med Hyg. 2018;99(2):428–34. https://doi.org/10.4269/ajtmh.18-0116.CrossRefPubMedPubMedCentral

39.

Clement F, Dewint P, Leroux-Roels G. Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen. J Clin Microbiol. 2002;40(12):4603–6. https://doi.org/10.1128/jcm.40.12.4603-4606.2002.CrossRefPubMedPubMedCentral

40.

Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP. Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980-2010). Am J Gastroenterol. 2012;107(9):1306–13. https://doi.org/10.1038/ajg.2012.141.CrossRefPubMed

41.

Si J, Li J, Zhang L, Zhang W, Yao J, Li T, et al. A signal amplification system on a lateral flow immunoassay detecting for hepatitis e-antigen in human blood samples. J Med Virol. 2019;91(7):1301–6. https://doi.org/10.1002/jmv.25452.CrossRefPubMed

42.

Gani AW, Wei W, Shi RZ, Ng E, Nguyen M, Chua MS, et al. An automated, quantitative, and multiplexed assay suitable for point-of-care hepatitis B virus diagnostics. Sci Rep. 2019;9(1):15615. https://doi.org/10.1038/s41598-019-52147-z.CrossRefPubMedPubMedCentral

43.

Ryu JH, Kwon M, Moon JD, Hwang MW, Lee JM, Park KH, et al. Development of a rapid automated fluorescent lateral flow immunoassay to detect hepatitis B surface antigen (HBsAg), antibody to HBsAg, and antibody to hepatitis C. Ann Lab Med. 2018;38(6):578–84. https://doi.org/10.3343/alm.2018.38.6.578.CrossRefPubMedPubMedCentral

44.

Nyan DC, Ulitzky LE, Cehan N, Williamson P, Winkelman V, Rios M, et al. Rapid detection of hepatitis B virus in blood plasma by a specific and sensitive loop-mediated isothermal amplification assay. Clin Infect Dis. 2014;59(1):16–23. https://doi.org/10.1093/cid/ciu210.CrossRefPubMedPubMedCentral

45.

Quoc NB, Phuong NDN, Chau NNB, Linh DTP. Closed tube loop-mediated isothermal amplification assay for rapid detection of hepatitis B virus in human blood. Heliyon. 2018;4(3):e00561. https://doi.org/10.1016/j.heliyon.2018.e00561.CrossRefPubMedPubMedCentral

46.

Cai T, Lou G, Yang J, Xu D, Meng Z. Development and evaluation of real-time loop-mediated isothermal amplification for hepatitis B virus DNA quantification: a new tool for HBV management. J Clin Virol. 2008;41(4):270–6. https://doi.org/10.1016/j.jcv.2007.11.025.CrossRefPubMed

47.

Cruz HM, de Paula SL, Salete de Paula V, Ferreira da Silva E, do Rodrigues ÓOKM, Pádua Milagres FA, et al. Evaluating HBsAg rapid test performance for different biological samples from low and high infection rate settings & populations. BMC Infect Dis. 2015;15:548. https://doi.org/10.1186/s12879-015-1249-5.CrossRefPubMedPubMedCentral

48.

Zhao N, Liu JX, Li D, Sun DX. Loop-mediated isothermal amplification for visual detection of hepatitis B virus. Zhonghua Gan Zang Bing Za Zhi. 2016;24(6):406–11. https://doi.org/10.3760/cma.j.issn.1007-3418.2016.06.003.CrossRefPubMed

49.

Zhou HY, Chen C, Li XN, Ma XJ. Loop-mediated isothermal amplification technique in the diagnosis of hepatitis B virus infection: a meta-analysis. Zhonghua Yu Fang Yi Xue Za Zhi. 2017;51(6):562–7. https://doi.org/10.3760/cma.j.issn.0253-9624.2017.06.020.CrossRefPubMed

50.

•• Abravanel F, Lhomme S, Tremeaux P, Migueres M, Harter A, Hasle C, et al. Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. Diagn Microbiol Infect Dis. 2020;96(2):114946. https://doi.org/10.1016/j.diagmicrobio.2019.114946Abravanel et al – This study confirms the high sensitivity, reproducibility, reliability, and ease of use of the Xpert HBV DNA load assay. Implementation of this assay will greatly improve the diagnosis of hepatitis B, particularly in LMIC and at POC.

51.

• Jackson K, Holgate T, Tekoaua R, Nicholson S, Littlejohn M, Locarnini S. Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing. J Med Virol. 2019. https://doi.org/10.1002/jmv.25485Jackson et al – This study demonstrates the applicability of dried blood spots for HBV serological and molecular testing and in particular HBV DNA viral loads.

52.

Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, et al. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. BMC Infect Dis. 2017;17(Suppl 1):700. https://doi.org/10.1186/s12879-017-2777-y.CrossRefPubMedPubMedCentral

53.

Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693. https://doi.org/10.1186/s12879-017-2776-z.CrossRefPubMedPubMedCentral

54.

Sullivan RP, Davies J, Binks P, Dhurrkay RG, Gurruwiwi GG, Bukulatjpi SM, et al. Point of care and oral fluid hepatitis B testing in remote indigenous communities of northern Australia. J Viral Hepat. 2020;27(4):407–14. https://doi.org/10.1111/jvh.13243.CrossRefPubMed

Titel: Point of Care Diagnostic Testing for Hepatitis B Virus
verfasst von: Kathy Jackson
Robert G. Gish
Publikationsdatum: 22.06.2020
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 3/2020
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-020-00531-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root

Early Transplantation in Acute on Chronic Liver Failure: Who and When

IgG4-Related Sclerosing Cholangitis

Targeting Viral cccDNA for Cure of Chronic Hepatitis B

Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation